Why NASDAQ:AMPH qualifies as a high growth stock.

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Key Considerations for Growth Investors.

• With a favorable Return on Equity (ROE) of 22.72%, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
• With a track record of beating EPS estimates in the last 4 quarters, AMPHASTAR PHARMACEUTICALS IN showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• The 1-year revenue growth of AMPHASTAR PHARMACEUTICALS IN (24.0%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• The quarter-to-quarter (Q2Q) revenue growth of 50.37% of AMPHASTAR PHARMACEUTICALS IN has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and drive revenue growth.
• With positive growth in its operating margin over the past year, AMPHASTAR PHARMACEUTICALS IN showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• With a favorable trend in its free cash flow (FCF) over the past year, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• The recent financial report of AMPHASTAR PHARMACEUTICALS IN demonstrates a 203.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• Analysts' average next Quarter EPS Estimate for AMPHASTAR PHARMACEUTICALS IN has witnessed a 23.76% change in the last 3 months, underscoring the dynamic nature of market sentiment towards the company's EPS prospects.
• The quarterly earnings of AMPHASTAR PHARMACEUTICALS IN have shown a 203.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• AMPHASTAR PHARMACEUTICALS IN shows accelerating EPS growth: when comparing the current Q2Q growth of 203.0% to the previous year Q2Q growth of -17.39%, we see the growth rate improving.

Zooming in on the fundamentals.

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

AMPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 203 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: AMPH is growing strongly while it also seems undervalued. These ratings would make AMPH suitable for value and growth investing!

Our latest full fundamental report of AMPH contains the most current fundamental analsysis.

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.